Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
90 hedge funds and large institutions have $189M invested in Endocyte, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 21 closing their positions.
11% less funds holding
Funds holding: 101 → 90 (-11)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
16% less call options, than puts
Call options by funds: $3.36M | Put options by funds: $4M
17% less capital invested
Capital invested by funds: $228M → $189M (-$39.1M)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$6.26M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$4.13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.57M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.79M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$1.9M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.85M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.52M |
| 4 |
SIM
Spark Investment Management
New York
|
-$1.15M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.14M |
ECYT Hedge Fund Activity: Q4 2013 in Review
90 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2013, worth a combined $189M — down 17% from $228M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ECYT and 11 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 30 added.
The largest buyer was UBS AM, opening a new position worth an estimated $6.26M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $1.9M.
- 90 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2013, down from 101 in Q3 2013.
- Funds reported $189M of Endocyte, Inc. Common Stock stock for Q4 2013, down 17% quarter-over-quarter.
- 11 funds opened new Endocyte, Inc. Common Stock positions in Q4 2013 and 21 closed out, a net change of -10 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q4 2013 was UBS AM, an estimated $6.26M added.
- The largest Endocyte, Inc. Common Stock seller in Q4 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $1.9M sold.
Based on aggregated 13F filings for Q4 2013.